Free Trial
NASDAQ:QURE

uniQure (QURE) Stock Price, News & Analysis

$4.76
-0.28 (-5.56%)
(As of 05/23/2024 ET)
Today's Range
$4.72
$5.04
50-Day Range
$4.39
$5.41
52-Week Range
$4.25
$21.00
Volume
469,832 shs
Average Volume
880,740 shs
Market Capitalization
$231.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.75

uniQure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
420.0% Upside
$24.75 Price Target
Short Interest
Bearish
6.72% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$339,845 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.61) to ($3.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.30 out of 5 stars

Medical Sector

735th out of 916 stocks

Pharmaceutical Preparations Industry

335th out of 412 stocks

QURE stock logo

About uniQure Stock (NASDAQ:QURE)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

QURE Stock Price History

QURE Stock News Headlines

uniQure: The AMT-130 Readout
5 unique date ideas in NW Arkansas - Axios
Amazon has a unique inflation problem - Reuters
See More Headlines
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
5/23/2024
Next Earnings (Estimated)
8/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:QURE
Employees
480
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.75
High Stock Price Target
$50.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+402.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-308,480,000.00
Net Margins
-1,562.22%
Pretax Margin
-1,542.31%

Debt

Sales & Book Value

Annual Sales
$19.00 million
Book Value
$3.02 per share

Miscellaneous

Free Float
46,248,000
Market Cap
$239.35 million
Optionable
Optionable
Beta
0.98
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

QURE Stock Analysis - Frequently Asked Questions

Should I buy or sell uniQure stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QURE shares.
View QURE analyst ratings
or view top-rated stocks.

What is uniQure's stock price target for 2024?

7 brokers have issued 12-month price targets for uniQure's stock. Their QURE share price targets range from $6.00 to $50.00. On average, they expect the company's share price to reach $24.75 in the next year. This suggests a possible upside of 420.0% from the stock's current price.
View analysts price targets for QURE
or view top-rated stocks among Wall Street analysts.

How have QURE shares performed in 2024?

uniQure's stock was trading at $6.77 at the beginning of 2024. Since then, QURE stock has decreased by 29.7% and is now trading at $4.76.
View the best growth stocks for 2024 here
.

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our QURE earnings forecast
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.54) by $0.01. The biotechnology company earned $6.69 million during the quarter, compared to the consensus estimate of $3.20 million. uniQure had a negative trailing twelve-month return on equity of 121.60% and a negative net margin of 1,562.22%.

What ETFs hold uniQure's stock?

ETFs with the largest weight of uniQure (NASDAQ:QURE) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM).iShares Genomics Immunology and Healthcare ETF (IDNA).

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

Who are uniQure's major shareholders?

uniQure's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.24%), BNP Paribas Financial Markets (1.54%), Acadian Asset Management LLC (1.28%), Privium Fund Management B.V. (1.21%), Ikarian Capital LLC (0.97%) and Carlson Capital L P (0.47%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Pierre Caloz, Rachelle Suzanne Jacques, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends
.

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QURE) was last updated on 5/23/2024 by MarketBeat.com Staff

From Our Partners